Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
|
|
- Ross Conley
- 6 years ago
- Views:
Transcription
1 Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) ! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / acb.sagepub.com Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay Richard Body 1,2, Gillian Burrows 3, Simon Carley 2,4 and Philip S Lewis 5 Abstract Objective: With a high-sensitivity troponin assay, it may be possible to exclude acute myocardial infarction with a single blood test on arrival in the emergency department by using a novel rule out cut-off set at the limit of detection of the assay. We aimed to determine whether this can also be achieved using a contemporary sensitive troponin assay that does not meet high-sensitivity criteria. Methods: In a prospective diagnostic cohort study, we included patients presenting to the emergency department with suspected cardiac chest pain. For this secondary analysis, serum samples drawn on arrival were tested using a contemporary sensitive troponin I assay (s-ctni; Siemens Ultra ADVIA Centaur, 99th percentile 40 ng/l, limit of detection 6 ng/ L). Acute myocardial infarction was adjudicated by two independent investigators based on reference standard troponin testing 512 h after symptom onset. Results: Of 414 participants, 70 (16.9%) had acute myocardial infarction and 205 (49.5%) had initial s-ctni concentrations below the limit of detection. Using the limit of detection as a rule out cut-off gave a sensitivity of 94.3% (95% CI %) for acute myocardial infarction. If only patients with s-ctni below the limit of detection and no electrocardiogram ischaemia were considered to have acute myocardial infarction ruled out (41.8% of the cohort, n ¼ 174), sensitivity would rise to 97.1% ( %) and negative predictive value to 98.8% ( %). Conclusions: Acute myocardial infarction cannot be excluded in patients with s-ctni concentrations below the limit of detection using the contemporary sensitive assay evaluated. Future work with this assay should focus on serial sampling over 1 3 h and combination with clinical information and/or additional biomarkers. Keywords Acute myocardial infarction, acute coronary syndromes, diagnosis, sensitivity and specificity, troponins, high sensitivity Accepted: 16th February 2015 Background The diagnosis of an acute myocardial infarction (AMI) hinges upon the detection of a rise and/or fall of cardiac troponin with at least one level above the 99th percentile of a healthy reference population. 1 With the increasing analytical sensitivity of modern assays, it is now possible to quantify troponin concentrations in 1 Cardiovascular Sciences Research Group, The University of Manchester, Manchester, UK 2 Emergency Department, Central Manchester NHS Foundation Trust, Manchester, UK 3 Biochemistry Department, Stockport NHS Foundation Trust, Stockport, UK 4 Centre for Effective Emergency Care, Manchester Metropolitan University, Manchester, UK 5 Cardiology Department, Stockport NHS Foundation Trust, Stockport, UK Corresponding author: Richard Body, Emergency Department, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. richard.body@manchester.ac.uk
2 544 Annals of Clinical Biochemistry 52(5) apparently healthy individuals, including concentrations that are below the 99th percentile of a reference population. For a troponin assay to be labelled as high sensitivity, it must (a) have adequate precision at the 99th percentile upper reference limit (defined as a coefficient of variation of <10%) and (b) detect troponin concentrations in over 50% of apparently healthy individuals. 2 The Roche high sensitivity troponin T (hs-ctnt; Elecsys 2010) and Abbott ARCHITECT high sensitivity troponin I are examples of assays that meet highsensitivity criteria. While the Siemens ADVIA Centaur troponin I assay also has adequate precision at the 99th percentile, it detects troponin concentrations in only 46% of apparently healthy individuals. 3 The assay has therefore been labelled as contemporary sensitive rather than high sensitivity. One of the key limitations of cardiac troponin as a biomarker of AMI is the time taken for circulating concentrations to rise after the onset of infarction. This means that patients who present to the emergency department (ED) with symptoms that are compatible with an acute coronary syndrome are routinely admitted to hospital for serial troponin testing over a number of hours. 1,4,5 Ultimately, however, only a minority of those patients will be diagnosed with AMI. 6,7 A strategy that would enable exclusion of that diagnosis in a proportion of patients at the time of initial presentation could reduce the need for serial sampling and therefore unnecessary hospital admissions. Using hs-ctnt we have previously shown that it may be possible to exclude AMI in up to 27.7% of patients who had completely undetectable troponin concentrations (<3 ng/l, which is labelled as the limit of blank of this assay). 8 In support of those findings and in a retrospective cohort of over 10,000 patients, Bandstein et al. 9 subsequently demonstrated that patients who have a normal electrocardiogram (ECG) and initial hs-ctnt concentrations below the limit of detection (LoD) of the assay (<5 ng/l) have extremely low probability of AMI, which may be considered to exclude the diagnosis. We do not yet know whether it would also be possible to exclude AMI in patients with initial troponin concentrations below the LoD of a contemporary sensitive (rather than high sensitivity ) assay such as the Siemens ADVIA Centaur troponin I Ultra. Goals of this investigation We sought to determine whether troponin concentrations below the LoD of a contemporary sensitive assay (Siemens ADVIA Centaur troponin I Ultra) could be used, either alone or in combination with the ECG, to exclude a diagnosis of AMI at the time of initial presentation to the ED. Methods Design, setting and selection of participants In this secondary analysis from a prospective diagnostic cohort study, we included patients who presented to the ED at Stepping Hill Hospital, Stockport, United Kingdom, with chest pain that the treating physician suspected might be cardiac. We excluded patients whose symptoms occurred >24 h prior to presentation, those with another medical condition necessitating hospital admission, patients with renal failure requiring dialysis, those with suspected myocardial contusion secondary to trauma, pregnant women, non-english speakers, prisoners and those for whom all means of follow up would be impossible. All participants provided written informed consent, and ethical approval was obtained from the Research Ethics Committee North West Cheshire (reference 09/H1014/74). From data collected in this cohort study, we have already published an external validation of the Manchester Acute Coronary Syndromes clinical decision rule, an evaluation of the diagnostic performance of the clinical judgement of emergency physicians and an analysis of the diagnostic value of pain severity Methods and measurements Clinical data were recorded at the time of presentation to the ED. ECGs were interpreted contemporaneously by the treating emergency physician, and the presence or absence of changes consistent with acute myocardial ischaemia (in the treating physician s opinion) was recorded in the case report form. All participants also underwent venepuncture at the time of initial presentation. Troponin T (ctnt, Roche Diagnostics Elecsys 4th generation, 99th percentile 10 ng/l, coefficient of variation <10% at 30 ng/l) was measured on arrival and at least 12 h after symptom onset, which formed the reference standard biomarker for AMI. Serum samples drawn at the time of presentation and 12 h after symptom onset were frozen at 70 C pending later testing for sensitive troponin I (s-ctni; Siemens troponin I Ultra, ADVIA Centaur). The 99th percentile of this assay is reported by the manufacturer as 40 ng/l. The lowest concentration, at which the coefficient of variation is <10%, is 30 ng/ L. The functional sensitivity of the assay (defined as the minimum troponin concentration with a coefficient of variation <20%) is 17 ng/l, and the LoD is 6 ng/l.
3 Body et al. 545 Follow up Patients were followed up after 30 days by (a) checking mortality status using a national database (the National Health Service Strategic Tracing Service database), (b) review of medical records and (c) either telephone, home visit or review in clinic. If it was not possible to contact the patient directly, their general practitioner (GP) was contacted. Follow-up was only considered valid in this event if the patient had been in contact with their GP and if sufficient information was available to determine ED attendances, hospital admissions, investigations and episodes of chest pain. If a patient had attended another hospital during the follow up period, copies of relevant records were obtained from that hospital. Outcomes The primary outcome for this analysis was a diagnosis of AMI. The diagnosis of AMI was adjudicated by two independent investigators with reference to clinical, laboratory and imaging data but blinded to s-ctni concentrations. Discrepancies were to be resolved by discussion although none occurred. AMI was defined in accordance with the third universal definition 13 and required a rise and/or fall of ctnt with at least one level above the 99th percentile (10 ng/l) and evidence of a rise and/or fall of at least 20 ng/l based on the analytical characteristics of the assay. As a secondary outcome, we also evaluated major adverse cardiac events (MACE) within 30 days, defined as AMI (including prevalent AMI diagnosed at the initial presentation), death (all cause) or the need for coronary revascularisation (including the detection of a new coronary stenosis >50% of the lumen of a major epicardial vessel, as reported by the responsible interventional cardiologist). Sensitivity analysis Recognising that our reference standard biomarker for AMI was troponin T, which may have different diagnostic performance to the troponin I assay being investigated, we also evaluated the diagnostic performance of the presentation s-ctni concentration for predicting a subsequent s-ctni rise to above the 99th percentile (40 ng/l) measured at least 12 h from symptom onset. To avoid incorporation bias, patients who presented to the ED more than 12 h after symptom onset were excluded from this analysis. Statistical analysis All statistical analyses were undertaken in SPSS version 20.0 (SPSS Inc, Chicago, Illinois) and/or MedCalc version (Mariakerke, Belgium). Baseline characteristics were summarised using descriptive statistics. To evaluate diagnostic performance, we calculated sensitivity, specificity, positive predictive values and negative predictive values together with 95% CI. We evaluated the overall diagnostic performance and also calculated the area under the receiver operating characteristic (ROC) curve. Results In total, 414 patients, who presented between April and July 2010, were eligible for inclusion in this analysis. All patients completed follow up at 30 days. In total, 70 (16.9%) patients had AMI and 86 (20.8%) patients developed MACE within 30 days (Figure 1). The baseline characteristics of participants are shown in Table 1. A comparison of the baseline characteristics of included patients with those who were excluded because no serum sample was available is shown in the Appendix (Supplementary Table 1). Included patients had a higher overall prevalence of angina but there were no other significant differences. In total, 16.4% (n ¼ 68) patients had initial s-ctni concentrations above the 99th percentile and 49.5% (n ¼ 205) had concentrations below the LoD of the assay (<6 ng/l); 41.8% (n ¼ 174) patients had both s-ctni concentrations <6 ng/l and no evidence of ECG ischaemia. For the diagnosis of AMI, concentrations of s-ctni at presentation had an area under the ROC curve of 0.95 (95% CI ). The diagnostic characteristics of the s-ctni assay at the time of presentation are shown in Tables 2 to 4. Table 2 shows the diagnostic characteristics for the primary outcome of AMI. At the 99th percentile cut-off, sensitivity was 75.6% (95% CI %). Sensitivity increased to 94.3% (95% CI %) at the LoD. Of the two patients with AMI missed by this strategy, both had elevated ctnt concentrations at the time of arrival (20 ng/l and 30 ng/l, respectively). Neither patient underwent coronary angiography. Both patients also had normal s-ctni concentrations 12 h after symptom onset (concentrations were 10 ng/l and 11 ng/l, respectively). If only patients with s-ctni below the LoD (<6 ng/ L) and no evidence of ECG ischaemia were considered to have the diagnosis ruled out, sensitivity would rise to 97.1% (95% CI %) and negative predictive value to 98.8% (95% CI %). Thus, this strategy would miss 2.9% (n ¼ 2) of AMIs and would mean that discharged patients have a 1.2% posttest probability of AMI. The findings were similar among patients whose time from symptom onset was both <6h and 56 h (see Supplementary Tables 2 and 3, available online).
4 546 Annals of Clinical Biochemistry 52(5) Figure 1. Participant flow diagram. Table 1. Baseline characteristics of included patients. Variable Total (n ¼ 414) Patients with AMI (n ¼ 70) Patients without AMI (n ¼ 344) Age in years, mean (SD) 63.7 (15.7) 71.9 (13.9) 62.0 (15.6) Men 238 (57.5) 45 (64.3) 193 (56.1) Previous angina 174 (42.0) 21 (30.0) 153 (44.5) Previous myocardial infarction 128 (30.9) 25 (35.7) 103 (29.9) Hypertension 170 (41.1) 35 (50.0) 135 (39.2) Hyperlipidaemia 162 (39.1) 29 (41.4) 133 (38.7) Diabetes mellitus 73 (17.6) 17 (24.3) 56 (16.3) Smoking 88 (21.3) 16 (22.9) 72 (20.9) Previous coronary intervention 64 (15.5) 8 (11.4) 56 (16.3) Time from symptom onset (hours; median, interquartile range) 3.5 ( ) 3.7 ( ) 3.3 ( ) AMI: acute myocardial infarction. Numbers relate to frequencies with percentages in parentheses unless otherwise stated. Table 3 shows the diagnostic performance of s-ctni for predicting the occurrence of MACE within 30 days. A total of 4.6% of patients who had an s- ctni concentration below the LoD (<6 ng/l) and who also had a normal ECG developed MACE within 30 days. Sensitivity analyses Because of the possibility that some patients may test positive for troponin T (which formed the reference standard for AMI in this study) but negative for troponin I (and vice versa), we ran a sensitivity analysis to
5 Body et al. 547 Table 2. Diagnostic performance of the Siemens sensitive troponin I (s-ctni) assay for diagnosing AMI at rule out cut-offs studied. Rule out strategy Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) s-ctni <40 ng/l (99th percentile) 75.6 ( ) 96.2 ( ) 80.9 ( ) 95.7 ( ) s-ctni <6 ng/l (limit of detection) 94.3 ( ) 59.6 ( ) 32.2 ( ) 98.1 ( ) s-ctni <40 ng/l and no ECG ischaemia a 87.1 ( ) 79.4 ( ) 46.2 ( ) 96.8 ( ) s-ctni <6 ng/l and no ECG ischaemia a 97.1 ( ) 49.7 ( ) 28.2 ( ) 98.8 ( ) PPV: positive negative values; NPV: negative predictive values. a Patients could be ruled out only if they have a s-ctni concentration below this threshold and no evidence of ECG ischaemia at the time of presentation to the ED. Table 3. Diagnostic performance of the Siemens troponin I (s-ctni) assay for MACE at rule out cut-offs studied. Rule out strategy Sensitivity Specificity PPV NPV s-ctni <40 ng/l (99th percentile) 69.8 ( ) 97.6 ( ) 88.2 ( ) 92.5 ( ) s-ctni <6 ng/l (limit of detection) 87.2 ( ) 60.4 ( ) 36.6 ( ) 94.7 ( ) s-ctni <40 ng/l and no ECG ischaemia a 80.2 ( ) 80.8 ( ) 52.3 ( ) 94.0 ( ) s-ctni <6 ng/l and no ECG ischaemia a 90.7 ( ) 50.3 ( ) 32.4 ( ) 95.4 ( ) PPV: positive negative values; NPV: negative predictive values. a Patients could be ruled out only if they have a s-ctni concentration below this threshold and no evidence of ECG ischaemia at the time of presentation to the ED. Table 4. Diagnostic performance of Siemens sensitive troponin I (s-ctni) concentrations at presentation for predicting any subsequent troponin I rise to above the 99th percentile at 12 h following symptom onset. Rule out strategy Sensitivity Specificity PPV NPV s-ctni <40 ng/l (99th percentile) 81.3 ( ) 99.3 ( ) 96.8 ( ) 95.0 ( ) s-ctni <6 ng/l (limit of detection) 93.3 ( ) 61.9 ( ) 40.7 ( ) 97.1 ( ) s-ctni <40 ng/l and no ECG ischaemia a 90.7 ( ) 79.9 ( ) 55.7 ( ) 96.8 ( ) s-ctni <6 ng/l and no ECG ischaemia a 97.3 ( ) 50.8 ( ) 35.6 ( ) 98.6 ( ) PPV: positive negative values; NPV: negative predictive values. a Patients could be ruled out only if they have a s-ctni concentration below this threshold and no evidence of ECG ischaemia at the time of presentation to the ED. evaluate the diagnostic performance of admission concentrations of s-ctni for predicting a subsequent elevation at 12 h. In total, 18.1% (75/343) patients who had a second sample analysed for s-ctni had a concentration of >40 ng/l after at least 12 h. The findings are summarised in Table 4 and are similar to the primary analysis. Patients with concentrations below the LoD (<6 ng/l) at the time of presentation and who had no ECG ischaemia had a 1.4% posttest probability of developing a subsequent s-ctni rise to >40 ng/l, giving a sensitivity of 97.3% (95% CI %) and negative predictive value 98.6% (95% CI %). Of the two patients who were missed by this strategy, one had presented within 1 h of symptom onset. That patient had a s-ctni concentration of 342 ng/l at 12 h. The patient also had a normal c-tnt (<10 ng/l) at admission, which rose to 50 ng/l at 12 h, and underwent percutaneous coronary intervention to a stenosed left anterior descending artery on an inpatient basis. The other patient who was missed by this strategy also presented 1 h after symptom onset and had a s-ctni concentration of 68 ng/l at 12 h. At the time of arrival, this patient did have an elevated ctnt of 40 ng/l. Discussion These findings suggest that the contemporary sensitive troponin I assay we have evaluated (Siemens ADVIA Centaur troponin I Ultra) has insufficient diagnostic sensitivity and negative predictive value to exclude
6 548 Annals of Clinical Biochemistry 52(5) AMI at the time of presentation to the ED using cut-offs below the 99th percentile. Among the 41.8% of patients who had initial s-ctni concentrations below the LoD and no evidence of ECG ischaemia, the posttest probabilities of AMI and MACE were found to be 1.2% and 4.6%, respectively. While this may be useful for risk stratification and to assist with triage to an appropriate level of inpatient care, this level of diagnostic accuracy is unlikely to be considered sufficient for clinicians to consider this a safe rule out strategy. 14 Using a high sensitivity troponin T assay (Roche Diagnostics 5th generation Elecsys, 99th percentile 14 ng/l, coefficient of variation <10% at 12 ng/l), previous work has shown that AMI could be excluded with very high negative predictive value in patients who have completely undetectable concentrations (below the limit of blank of the assay, <3 ng/l) at the time of initial presentation. 8,15 A further retrospective evaluation of over 14,000 patients suggested that patients with initial concentrations below the LoD of the assay (5 ng/l) and no ECG evidence of ischaemia have a very low probability of AMI. 9 The troponin I assay that we have evaluated meets precision criteria for a high sensitivity assay (coefficient of variation <10% at the 99th percentile) but does not detect troponin concentrations in >50% of healthy individuals. Thus, it is labelled as a contemporary sensitive assay rather than as having high sensitivity. 2 The diagnostic performance of this assay at the conventional 99th percentile cut-off has been shown to be similar to high sensitivity assays. 16 With serial testing over 3 h, it may be possible to exclude AMI with high diagnostic sensitivity using this troponin I assay. 6 In this research, we determined whether the detection of extremely low troponin concentrations by this assay at the time of arrival in the ED could be used immediately to exclude AMI in a proportion of patients. We found that the diagnostic performance of this assay at the conventional 99th percentile cut-off is comparable to that reported by Collinson et al. 17 In a cohort of 850 patients, that group reported a sensitivity of 73.0%. Keller et al. 6 reported a higher sensitivity of 90.2%. However, our findings suggest that sensitivity remains suboptimal to exclude the diagnosis of AMI even at the unconventional cut-off set at the LoD of the assay. Limitations This study does have some important limitations. First, of the 477 patients who participated in this study in total, only 414 patients had serum aliquots available for this analysis. This raises the possibility of selection bias, although the baseline characteristics of those included were not significantly different to those without available serum samples. Second, our reference standard for AMI was a troponin T assay at 512 h. A small proportion of patients with a rise and/or fall of troponin T may not have a detectable rise and/or fall of troponin I (and vice versa), which could have led to underestimates of diagnostic performance given that we were evaluating a contemporary sensitive troponin I assay. To address this, we included a sensitivity analysis evaluating the diagnostic performance of initial troponin I concentrations for predicting subsequent troponin I elevations, which demonstrates that the conclusions drawn would remain unchanged. While it is important to recognise these limitations, it is therefore unlikely that they have affected our findings. Finally, it is important to consider the precision of the assay at such low troponin concentrations. The functional sensitivity of the Siemens ADVIA Centaur troponin I Ultra assay, at which the coefficient of variation is below 20%, is 17 ng/l. Because of concerns about precision below that concentration, some laboratories would not report lower concentrations. The precision of the assay may have contributed to our findings and presents a further barrier to clinical implementation of a rule out cut-off set at the LoD of this assay. It is important, also, to recognise that samples in this study were analysed in batches, which could have reduced the impact of precision on our findings. Conclusions In summary, troponin I concentrations measured using a contemporary sensitive assay cannot be used to exclude AMI at the time of presentation to the ED, even among patients who have concentrations below the LoD of the assay and a normal ECG. Further research should focus on (a) the combination of troponin concentrations with additional clinical information and/or alternative biomarkers and (b) the earliest time point at which AMI can be safely excluded with serial sampling. Acknowledgements We acknowledge the support of the Manchester Academic Health Science Centre, the Manchester Biomedical Research Centre and the National Institute for Health Research (United Kingdom). We also acknowledge the support of all the staff in the Emergency Department and Biochemistry Department at Stepping Hill Hospital who assisted with this work, in particular Sister Joanna Jarvis. Declaration of conflicting interests For the purposes of this research, reagents were donated to the research team without charge by Siemens Diagnostics. For additional analyses from this cohort study (not reported here), Roche Diagnostics and Abbott Laboratories also donated reagents without charge. Dr Body has undertaken
7 Body et al. 549 other research using reagents that were donated without charge by Roche Diagnostics, Siemens Diagnostics, Abbott Laboratories, Alere Diagnostics and Randox Laboratories. Dr Body has accepted travel and accommodation for conferences from Roche Diagnostics and Randox Laboratories. Dr Body is a principal investigator for a study sponsored by Roche Diagnostics. Dr Lewis has accepted travel and accommodation to lecture for Randox Laboratories. Funding This study was funded by a grant from the United Kingdom College of Emergency Medicine and was supported by: (a) fellowship funding (an Academic Clinical Lectureship for the first author) from the United Kingdom National Institute for Health Research (NIHR), (b) by the NIHR Clinical Research Network (UK CRN 8376) and (c) reagents donated for the purposes of the research by Siemens. Ethical approval This study was approved by the Research Ethics Committee North West Cheshire (reference 09/H1014/74). Guarantor RB. Contributorship RB conceived the study. RB, GB and PL were involved in protocol development. RB gained ethical approval, supervised/undertook patient recruitment and data analysis. RB and SC adjudicated patient outcomes. RB wrote the first draft of the manuscript, and the analyses were critically reviewed by all authors. All authors reviewed and edited the manuscript and approved the final version of the manuscript. References 1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: Apple FS and Collinson PO IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2011; 58: Collinson PO, Clifford-Mobley O, Gaze D, et al. Assay imprecision and 99th-percentile reference value of a highsensitivity cardiac troponin I assay. Clin Chem 2009; 55: National Clinical Guideline Centre for Acute and Chronic Conditions. Chest pain of recent onset: NICE guideline. Manchester: National Clinical Guideline Centre for Acute and Chronic Conditions, Authors/Task Force Members, Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. New Engl J Med 2009; 361: Cullen L, Mueller C, Parsonage WA, et al. Validation of high sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. JAm Coll Cardiol 2013; 62: Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol 2011; 58: Bandstein N, Ljung R, Johansson M, et al. Undetectable high sensitivity troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014; 63: Body R, Carley S, McDowell G, et al. The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: derivation and external validation. Heart 2014; 100: Body R, Cook G, Burrows G, et al. Can emergency physicians rule in and rule out acute myocardial infarction with clinical judgement? Emerg Med J 2014; 31: Body R, Lewis PS, Carley S, et al. Chest pain: if it hurts a lot, is heart attack more likely? Eur J Emerg Med. Epub ahead of print 21 October DOI: / MEJ Thygesen K, Alpert JS and White HD. On behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 2007; 116: Than M, Herbert M, Flaws D, et al. What is an acceptable risk of major adverse cardiac event in chest pain patients soon after discharge from the emergency department? Int J Cardiol 2013; 166: Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity cardiac troponin T measurement in the emergency department. Am J Med 2010; 123: Mueller M, Celik S, Biener M, et al. Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive troponin I assay in patients with acute coronary syndrome. Clin Res Cardiol 2012; 101: Collinson P, Gaze D and Goodacre S. Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain. Heart 2014; 100:
High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation
Clinical Chemistry 61:7 983 989 (2015) Proteomics and Protein Markers High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective
More informationLow concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationBetter, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays
Editorial Page 1 of 5 Better, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays Noreen van der Linden, Alexander S. Streng, Will K. W. H.
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity
More informationBioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationBertil Lindahl Akademiska sjukhuset Uppsala
Bertil Lindahl Akademiska sjukhuset Uppsala Kriterier för akut hjärtinfarkt Bevis på myokardskada/nekros: Konstaterad höjning och/eller sänkning av biomarkörer (företrädesvis troponin) med minst ett värde
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationRapid rule out of acute myocardial infarction: novel biomarker-based strategies
653229ACC0010.1177/2048872616653229European Heart Journal: Acute Cardiovascular CareMueller et al. research-article2016 Original scientific paper Rapid rule out of acute myocardial infarction: novel biomarker-based
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationRapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.
Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD
More informationPerformance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis
Performance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis Ayman Al-Saleh MD, Ashraf Alazzoni MD, Saleh Al Shalash MD, Chenglin Ye
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationCongreso Nacional del Laboratorio Clínico 2016
Can biomarkers help us make a better use of cardiac imaging for myocardial ischaemia rule-out in the Emergency Department? Alessandro Sionis Director Acute and Intensive Cardiac Care Unit Hospital de la
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationDolore Toracico e Livelli di Troponina non Misurabili
Dolore Toracico e Livelli di Troponina non Misurabili Andrea Fabbri Dipartimento di Emergenza Presidio Ospedaliero Morgagni Pierantoni Azienda USL Romagna Forlì andrea.fabbri@auslromagna.it Rapid Exclusion
More informationWaiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad
Waiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad Fred Apple PhD Hennepin County Medical Center University of Minnesota
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationDiagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance
More informationHigh-Sensitivity Troponin: Star Player but No Lone Hero
Article: Richard Body.. Clin Chem 2017;63:1555-1556. http://clinchem.aaccjnls.org/content/63/10/1555 Guest: Dr. Richard Body is a professor of Emergency Medicine at the University of Manchester in the
More informationValidation of an accelerated high-sensitivity troponin T assay protocol in an Australian cohort with chest pain
Elevation of cardiac troponin (ctn) levels is central to the definition of acute myocardial infarction (AMI). 1 Increasingly sensitive ctn assays offer the potential for AMI to be diagnosed earlier than
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationHigh-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study
High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study Anoop S V Shah*, Atul Anand*, Yader Sandoval, Kuan Ken Lee, Stephen W Smith, Philip
More informationThe state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T
Editorial Page 1 of 5 The state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T Aldo Clerico 1, Giuseppe Lippi 2 1 Scuola Superiore Sant Anna and Fondazione CNR Regione
More informationHigh-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor
More informationEARLY DIAGNOSIS AND RISK STRATIFICATION IN PATIENTS WITH SYMPTOMS SUGGESTIVE OF ACUTE CORONARY SYNDROME
DEPARTMENT OF CLINICAL SCIENCE AND EDUCATION, SÖDERSJUKHUSET Karolinska Institutet, Stockholm, Sweden EARLY DIAGNOSIS AND RISK STRATIFICATION IN PATIENTS WITH SYMPTOMS SUGGESTIVE OF ACUTE CORONARY SYNDROME
More informationHeart-type fatty acid-binding protein in early diagnosis of acute myocardial infarction in comparison to sensitive troponin I
Heart-type fatty acid-binding protein in early diagnosis of acute myocardial infarction in comparison to sensitive troponin I E. Czyz 1, S. Tzikas 1, A. Schulz 1, T. Zeller 1,3, S. Baldus 3, C. Bickel
More informationRecent community campaigns on
Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry Use of hs troponin testing of patients hospitalised with possible ACS was associated
More informationD DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2
Journal of Health Science 2 (2014) 523-528 doi: 10.17265/2328-7136/2014.11.001 D DAVID PUBLISHING Management, Triage and Outcomes of 378 Patients Presenting to the Emergency Department with Chest Pain
More informationKeywords Acute coronary syndromes, High sensitivity cardiac markers, Malta, Troponin T, Myocardial infarction
Did the introduction of high-sensitivity Troponin T for the assessment of suspected acute coronary syndrome in Malta result in reduction of hospitalization time? A retrospective review Ahmed Chilmeran,
More informationHigh-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study
DATA SUPPLEMENT High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study Anoop SV Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister,
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Speaker: Date: Location: Troponin State of the Art: Past, Present and Future Yader Sandoval, MD Cardiovascular Disease Fellow Minneapolis Heart Institute at Abbott
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationConference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications
Conference Papers in Medicine, Article ID 583175, 5 pages http://dx.doi.org/10.1155/2013/583175 Conference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction:
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationThe clinical performance of the novel POC Minicare ctni-assay. Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden
The clinical performance of the novel POC Minicare ctni-assay Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden Disclosure: Per Venge has received consultancy honoraria
More informationThe NICE chest pain guideline 1 year on. Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust
The NICE chest pain guideline 1 year on Jane S Skinner Consultant Community Cardiologist The Newcastle upon Tyne Hospitals NHS Foundation Trust The Society for Acute Medicine, 5 th International Conference,
More informationThe utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department
Accepted Manuscript The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department John W. Pickering, Joanna M. Young, Peter George,
More informationEarly Rule-Out and Rule-In Strategies for Myocardial Infarction
Papers in Press. Published October 10, 2016 as doi:10.1373/clinchem.2016.254730 The latest version is at http://hwmaint.clinchem.aaccjnls.org/cgi/doi/10.1373/clinchem.2016.254730 Clinical Chemistry 63:1
More informationDocument Version Publisher s PDF, also known as Version of Record (includes final page, issue and volume numbers)
Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.H. Published
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationRuling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations
European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass
More informationInternational Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:
International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp. 072-078, September, 2018. www.premierpublishers.org, ISSN: 3102-9869 IJCCR Research Article Copeptin as a Novel Biomarker
More informationImproving the detection of myocardial infarction in women
Improving the detection of myocardial infarction in women British Cardiac Society Listening to the Female Voice 4 th June 2014 anoopsshah@gmail.com Dr Anoop Shah BHF Centre for Cardiovascular Sciences
More informationChest Pain Typicality in Suspected Acute Coronary Syndromes and the Impact of Clinical Experience
CLINICAL RESEARCH STUDY Chest Pain Typicality in Suspected Acute Coronary Syndromes and the Impact of Clinical Experience Edward W. Carlton, MBChB, a,b Martin Than, MBBS, c Louise Cullen, MBBS, d Ahmed
More informationAvailable online at
152 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 2, 2015 The Distribution of Abbott High-Sensitivity Troponin I Levels in Korean Patients with Chest Pain
More informationTITLE: Cardiac Troponin for the Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Review of Guidelines
TITLE: Cardiac Troponin for the Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Review of Guidelines DATE: 11 January 2013 CONTEXT AND POLICY ISSUES Cardiac troponin (ctn) is a cardiomyocyte-specific
More informationORIGINAL ARTICLE Determination of the 99th percentile upper reference limit for highsensitivity cardiac troponin I in Malaysian population
Malaysian J Pathol 2017; 39(2) : 135 140 ORIGINAL ARTICLE Determination of the 99th percentile upper reference limit for highsensitivity cardiac troponin I in Malaysian population Say Min LIM MD, Subashini
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationHigh-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department
Original Article Page 1 of 5 High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department Giuseppe Lippi 1, Fabian Sanchis-Gomar 2,3,4, Rosalia
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG95) Chest pain of recent onset: Assessment and diagnosis
More informationRESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome
RESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome Page 1 Responses were received from: 1. Chemical Pathology Clinical Stream,
More informationUndetectable High-Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Journal of the American College of Cardiology Vol. 63, No. 23, 2014 Ó 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. Open access under CC BY-NC-ND
More informationUnnecessary hospitalisation and investigation of low risk patients presenting to hospital with chest pain
Unnecessary hospitalisation and investigation of low risk patients presenting to hospital with chest pain Michael Perera Advanced Trainee in General and Acute Medicine Leena Aggarwal Director, Medical
More informationNew universal definition of myocardial infarction
New universal definition of myocardial infarction L. K. Michalis, ΜRCP, FESC Professor of Cardiology, University of Ioannina Changing Criteria for definition of MI Primarily clinical & ECG approach First
More informationDiagnostic algorithms for acute coronary syndrome is one better than another?
Review Article Page 1 of 6 Diagnostic algorithms for acute coronary syndrome is one better than another? Gianfranco Cervellin 1, Camilla Mattiuzzi 2, Chiara Bovo 3, Giuseppe Lippi 4 1 Emergency Department,
More informationCanadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé. Supporting Informed Decisions
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal Use Report March 2013 Volume 2, Issue 1B Recommendations for the Use
More informationThe Clinical Laboratory Working with Physicians to Improve Patient Care
The Clinical Laboratory Working with Physicians to Improve Patient Care Michael A. Pesce, PhD Professor Emeritus Columbia University Medical Center Department of Pathology and Cell Biology Objectives Troponin
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationIs it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention
Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention DA Jones, J Howard, S Gallagher, KS Rathod, A Jain, S Mohiddin, C Knight, A Mathur, EJ
More informationImpact of Chest Pain Protocol Targeting Intermediate Cardiac Risk Patients in an Observation Unit of an Academic Tertiary Care Center
Elmer ress Original Article J Clin Med Res. 2016;8(2):111-115 Impact of Chest Pain Protocol Targeting Intermediate Cardiac Risk Patients in an Observation Unit of an Academic Tertiary Care Center Tariq
More informationEvaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation
Clinical Chemistry 64:5 820 829 (2018) Proteomics and Protein Markers Evaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation Jaimi Greenslade,
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Accepted Manuscript Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD Rickard Ljung, MD, PHD Magnus Johansson, MD,
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationImpact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction
doi: 10.2169/internalmedicine.8510-16 http://internmed.jp ORIGINAL ARTICLE Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction Taro Ichise, Hayato
More informationWhat is the Yield of Testing for Coronary Artery Disease after an Emergency Department Attendance with Chest Pain?
Heart, Lung and Circulation (2016) 25, 12 18 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2015.05.025 ORIGINAL ARTICLE What is the Yield of Testing for Coronary Artery Disease after an Emergency
More informationCLINICAL GUIDANCE FRAMEWORKS
IMPROVING CARE PROCESSES FOR PATIENTS WITH POSSIBLE SUSPECTED ACUTE CORONARY SYNDROME (ICARE-ACS): A NATIONAL IMPLEMENTATION TRIAL OF A CLINICAL GUIDANCE FRAMEWORK S Aldous; on behalf of the IcareACS team
More informationCardiac Troponin: Current Status and Future Promise
Cardiac Troponin: Current Status and Future Promise Robert H. Christenson, Ph.D., ABCC, FACB Professor of Pathology Professor of Medical and Research Technology University of Maryland School of Medicine
More informationQuantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass
Quantitative measurement of 6 analytes in parallel hs Trop I, NTproBNP, D-Dimer, hscrp, Myoglobin, HCG, CK-MB mass High Sensitivity NEW MARKER Tr o p o n in I EMERGENCY & CRITICAL CARE» 6 samples in parallel»
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationPaul Jülicher, 1 Jaimi H Greenslade, 2 William A Parsonage, 3 Louise Cullen 2. Open Access. Research
To cite: Jülicher P, Greenslade JH, Parsonage WA, et al. The organisational value of diagnostic strategies using high-sensitivity troponin for patients with possible acute coronary syndromes: a trialbased
More informationKeywords Troponin (I and T), high sensitive, gastro-intestinal, abdominal surgery, goal-directed therapy
Original Article Annals of Clinical Biochemistry 2014, Vol. 51(2) 258 268! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563213494078 acb.sagepub.com
More informationEffective Health Care Program
Comparative Effectiveness Review Number 135 Effective Health Care Program Cardiac Troponins Used as Diagnostic and Prognostic Tests in Patients With Kidney Disease Executive Summary Background Cardiac
More informationSerial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction JAMA. 2011;306(24):
ORIGINAL CONTRIBUTION Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction Till Keller, MD Tanja Zeller, PhD Francisco Ojeda, PhD Stergios Tzikas, MD Lars Lillpopp
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationFifty shades of Troponin. Dr Liam Penny The Queens Hotel, Cheltenham 4 th October 2012
Fifty shades of Troponin Dr Liam Penny The Queens Hotel, Cheltenham 4 th October 2012 Plaque-fissure and intracoronary thrombus Courtesy Prof. MJ Davies Acute Coronary Syndromes Plaque-fissure and intracoronary
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationAcute Myocardial Infarction: Difference in the Treatment between Men and Women
Quality Assurance in Hcahh Can, Vol. 5, No. 3, pp. 261-265,1993 Printed in Great Britain 1040-6166/93 $6.00 + 0.00 1993 Pergamon Press Ltd Acute Myocardial Infarction: Difference in the Treatment between
More informationAcute Coronary Syndromes
High-sensitivity Troponins Difficult Friends in Acute Coronary Syndromes Roland Klingenberg, Christian M Matter, 2 Christophe Wyss, Danielle Hof, Arnold von Eckardstein and Thomas F Lüscher 6. Clinical
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationPolicy Register No: Status: Public. Contributes to Care Quality Commission Outcome 4
Operational Policy for Transfer of ST Elevation MI (STEMI) patients to Essex Cardiothoracic Centre (ECTC) for Primary Percutaneous Coronary Intervention Policy Register No: 09122 Status: Public Developed
More informationProspective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay
CMAJ Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay Tobias Reichlin MD, Raphael Twerenbold MD, Karin
More information